Danaher is a diversified life-sciences and diagnostics platform spanning three segments: Life Sciences (mass spectrometers, flow cytometry, genomics, bioprocess technologies), Diagnostics (chemistry, immunoassay, microbiology, hematology, molecular and pathology systems), and Environmental & Applied Solutions (water quality and product-identification instrumentation).
DHR
· Healthcare · Medical - Diagnostics & Research
· Market cap $155.44B
QuantHub Original Research · Updated 2026-09-23
·
High QualityA-tier business, B-tier valuation with 29.6% upside to $286.52 blended fair value.CheapIn Buy Zone
DHR is 28% below fair value and in its buy zone. Consider adding to your position.
QuantHub Research: Investment Thesis
Maturing Phase
Danaher is a diversified life-sciences and diagnostics platform spanning three segments: Life Sciences (mass spectrometers, flow cytometry, genomics, bioprocess technologies), Diagnostics (chemistry, immunoassay, microbiology, hematology, molecular and pathology systems), and Environmental & Applied Solutions (water quality and product-identification instrumentation). The business quality is high, anchored in intangible assets and switching costs: instruments are embedded in regulated laboratory workflows, and the consumables, reagents and service annuity that follows an installed base produces TTM gross margin of 58.5% and TTM operating margin of 20.4%. Growth has re-accelerated modestly, with revenue up 5.5% and earnings up 56.8% in the most recent quarter, while TTM net margin of 15.9% and ROE of 7.7% show the earnings base is still recovering rather than fully normalized. The shares are mispriced to the downside of intrinsic value: at $221.12 the stock trades at 38.95x trailing earnings, 28.53x free cash flow and 24.84x EV/EBITDA, yet the blended fair value estimate of $286.52 implies 29.6% upside, and the historical-multiple regime screens as cheap. Analyst consensus is Strong Buy with a $250 average target, 13.1% above the current price, so the market is pricing a slower core-growth trajectory than the franchise's cash-generation and margin structure justify. The central debate is whether mid-single-digit core growth plus margin recovery can close the gap to fair value before the CEO transition and integration of Masimo and StatLab absorb management attention.
Danaher is undervalued versus blended fair value but not versus its own history: the stock trades at 38.95x trailing earnings, 28.53x free cash flow and 24.84x EV/EBITDA, multiples that sit above where the shares have historically changed hands, which is why the historical-multiple regime screens as cheap only in relative terms. The gap between the $221.12 price and the $286.52 fair value estimate reflects a market that is discounting the 5.5% most-recent-quarter revenue growth and 7.7% ROE as evidence of a still-subdued core, while capitalizing the 56.8% most-recent-quarter earnings growth and 58.5% TTM gross margin at a discount. Analyst consensus is Strong Buy with a $250 average target, 13.1% above the current price, meaning sell-side analysts see less upside than the blended fair value model; that spread suggests the market is waiting for evidence that core growth can hold within the guided 3.0% to 4.0% 2026 range before re-rating the multiple. The pending Masimo integration and StatLab transaction add execution and regulatory-clearance uncertainty that keeps a lid on the multiple despite the franchise's recurring consumables and service revenue.
12–18 Month Outlook
In 18 months Danaher should be a post-transition company: Julie Sawyer Montgomery will have been CEO since October 1, 2026, the Masimo integration will be further along, and the StatLab transaction will either have closed after regulatory clearance or be visibly delayed. The key question is whether core growth can hold within the guided 3.0% to 4.0% 2026 range; the most recent quarter showed 5.5% revenue growth and 56.8% earnings growth, and if that trajectory persists the 29.6% gap to the $286.52 fair value estimate can narrow. If core growth slips below the guided range, the 38.95x trailing earnings and 28.53x free cash flow multiples leave limited downside protection, and the stock could trade closer to the $250 analyst average target or below. The 7.7% ROE needs to improve for the premium multiple to be sustained, and the unresolved Masimo legal matters, including the October 2026 Willow arbitration hearing, remain a swing factor for sentiment.
Bull vs Bear
Bull Case
The blended fair value estimate of $286.52 implies 29.6% upside from the $221.12 current price, and the historical-multiple regime classifies the shares as cheap, giving a valuation cushion if core growth merely holds.
TTM gross margin of 58.5% and TTM operating margin of 20.4% demonstrate pricing power and a consumables-and-service mix that converts revenue into cash at $7.75 of free cash flow per share.
Earnings grew 56.8% year over year in the most recent quarter on 5.5% revenue growth, showing operating leverage as the earnings base normalizes from prior-cycle pressure.
Analyst consensus is Strong Buy with a $250 average target, 13.1% above the current price, indicating sell-side expectations remain constructive on the Diagnostics and Life Sciences franchise.
Julie Sawyer Montgomery, whose Diagnostics track record includes growing revenue from about $6.0 billion in 2017 to about $11.0 billion by August 2026, is scheduled to become President and CEO on October 1, 2026, bringing a proven operator into the top role.
Bear Case
The stock is not cheap on absolute multiples: 38.95x trailing earnings, 28.53x free cash flow and 24.84x EV/EBITDA leave little room for error if core growth falls below the guided 3.0% to 4.0% 2026 range.
ROE of 7.7% is modest for a company trading at a premium multiple, indicating the capital base is not yet generating the returns that would justify a higher rating.
Masimo carries DOJ subpoena and civil investigative demand exposure concerning Rad-G and Rad-97 products and recalls, a supplemental grand-jury subpoena received in February 2026, multiple related litigation matters and an October 2026 Willow arbitration hearing, creating legal and integration overhang.
Rainer M. Blair retires as CEO on October 1, 2026, while Julie Sawyer Montgomery takes over during Masimo integration and the pending StatLab transaction, concentrating execution demands in a new leadership team.
Healthcare regulation, reimbursement, product approvals, clinical-trial requirements and off-label marketing rules can affect product sales and compliance costs, and StatLab requires regulatory clearance before closing.
Leadership & Competitive Position
Rainer Blair
Beats guidance75% of qtrs
Capital allocationGood
Rainer M. Blair is the current CEO and is scheduled to retire on October 1, 2026, with Julie Sawyer Montgomery succeeding him as President and CEO. Sawyer Montgomery's Diagnostics track record includes growing revenue from about $6.0 billion in 2017 to about $11.0 billion by August 2026, which supports a good assessment of the incoming leadership's operating capability. The transition occurs while Masimo integration and the pending StatLab transaction are underway, so the new team inherits a concentrated execution agenda.
Competitive Moat
stable
switching costsintangible assets
Danaher competes across life-sciences instrumentation, diagnostics and water-quality analysis, with an installed base of instruments tied to consumables, reagents and service contracts. The research describes broad segment breadth across Life Sciences, Diagnostics and Environmental & Applied Solutions but does not disclose specific market-share percentages.
Disruption: Medium, because rapid diagnostics, AI and digital-workflow innovation, lower-cost entrants and changes in customer preferences could erode Danaher's positions if product development and commercialization fall behind market needs.
QuantHub Research
Valuation
Multiple
Current
Median 3yr
Median 5yr
Min 5yr
Max 5yr
P/E
38.95x
43.07x
35.92x
24.01x
45.15x
P/S
6.19x
7.03x
7.03x
6.4x
7.13x
P/FCF
28.53x
30.78x
29.5x
23.16x
31.68x
P/S 6.19x vs 5yr range 6.4-7.13x (P25=6.4x, median=7.03x, P75=7.08x)
Price Outlook (5-Year)
Bear
$229
0.4%/yr
Base
$287
5.0%/yr
fair value
Bull
$344
8.9%/yr
Bear/Base/Bull anchored to QuantHub fair value estimate. Base = headline fair value; Bear −20%; Bull +20%.
Healthcare regulation, reimbursement, product approvals, clinical-trial requirements, off-label marketing rules and regulatory proceedings can affect product sales and compliance costs. StatLab also requires regulatory clearance before closing.
Masimo Legal and Product Matters
high
Masimo carries DOJ subpoena and civil investigative demand exposure concerning Rad-G and Rad-97 products and recalls, a supplemental grand-jury subpoena received in February 2026, multiple related litigation matters and an October 2026 Willow arbitration hearing.
Technological Disruption
medium
Rapid diagnostics, AI and digital-workflow innovation, lower-cost entrants and changes in customer preferences could erode Danaher's positions if product development and commercialization fall behind market needs.
Macroeconomic Slowdown
medium
A weaker macroeconomic environment, trade-policy changes or reduced biopharma and research spending could slow demand for instruments, consumables and services, particularly in biotechnology and life-sciences end markets.
Valuation Risk
medium
Although undervalued versus the $286.52 blended fair value estimate, Danaher trades at 38.95x trailing earnings, 28.53x free cash flow and 24.84x EV/EBITDA. Growth below the guided 3.0% to 4.0% 2026 core range could pressure the multiple.
Leadership Transition
medium
Rainer M. Blair will retire as CEO on October 1, 2026, while Julie Sawyer Montgomery takes over during Masimo integration and the pending StatLab transaction, concentrating execution demands in a new leadership team.
Growth Engines
Diagnostics franchise expansionmature
Hospitals, physicians' offices, reference laboratories and critical-care settings require chemistry, immunoassay, microbiology, hematology, molecular and pathology systems with recurring reagent and service revenue.
Life Sciences bioprocessingmature
Biopharma and research customers require bioprocess technologies, consumables, filtration, separation and purification systems tied to gene and cell therapy development.
Masimo integration synergiesearly
The Masimo acquisition adds patient-monitoring and diagnostics assets, though DOJ subpoena and civil investigative demand exposure concerning Rad-G and Rad-97 products and recalls creates integration uncertainty.
StatLab pathology acquisitionearly
StatLab adds pathology diagnostics capability but requires regulatory clearance before the transaction can close.
Danaher research profile updated with current financial and leadership data
The profile confirms Rainer Blair as CEO, 59,000 full-time employees, and the three-segment structure across Life Sciences, Diagnostics and Environmental & Applied Solutions, with the CEO transition to Julie Sawyer Montgomery scheduled for October 1, 2026.
This is AI-powered fundamental analysis built from scratch — not aggregated analyst ratings. Get this research for your entire portfolio plus daily briefings, research signals, and options income.
QuantHub research is focused on quality businesses with durable competitive advantages — companies we'd want to own for 3–5 years or more. We are not short-term traders. Every analysis is built around a single question: is this a great business available at a reasonable price for a long-term investor?
We start where most analysts finish: the fundamentals. For every company, our AI ingests years of financial statements — revenue, margins, free cash flow, and how the business has been valued by the market across multiple cycles. But numbers alone don't tell you whether a business is worth owning.
The harder work is qualitative. We assess the competitive moat: is it widening or eroding? We read the leadership track record — how capital has been allocated, whether management has earned trust through consistent execution. We look at what the market is afraid of, and whether that fear is priced in fairly or irrationally.
Valuation is always relative. A stock is cheap or expensive compared to its own history. We build scenario matrices anchored to 5-year historical multiples, then ask: what has to go right for the upside case, and what's the floor if it doesn't?
Finally, we write an 18-month forward outlook — not a price target, but a mental model of where this business will be and what the narrative will look like. Every note is dated and versioned. When material facts change, we update the thesis.
Frequently Asked Questions
Is DHR undervalued?
Yes, DHR appears undervalued at the current price of $224.65, trading below our fair value estimate of $286.52 (+28% upside). QuantHub considers this a buy zone.
What is DHR's fair value?
QuantHub Research estimates DHR's fair value at $286.52 based on our proprietary valuation model incorporating historical P/S, P/E, and P/FCF multiples over a 5-year range.
What are the key risks for DHR?
Regulatory Changes: Healthcare regulation, reimbursement, product approvals, clinical-trial requirements, off-label marketing rules and regulatory proceedings can affect product sales and compliance costs. StatLab also requires regulatory clearance before closing. Masimo Legal and Product Matters: Masimo carries DOJ subpoena and civil investigative demand exposure concerning Rad-G and Rad-97 products and recalls, a supplemental grand-jury subpoena received in February 2026, multiple related litigation matters and an October 2026 Willow arbitration hearing. Technological Disruption: Rapid diagnostics, AI and digital-workflow innovation, lower-cost entrants and changes in customer preferences could erode Danaher's positions if product development and commercialization fall behind market needs.
What is the bull case for DHR?
The blended fair value estimate of $286.52 implies 29.6% upside from the $221.12 current price, and the historical-multiple regime classifies the shares as cheap, giving a valuation cushion if core growth merely holds. TTM gross margin of 58.5% and TTM operating margin of 20.4% demonstrate pricing power and a consumables-and-service mix that converts revenue into cash at $7.75 of free cash flow per share. Earnings grew 56.8% year over year in the most recent quarter on 5.5% revenue growth, showi
How confident is QuantHub in DHR?
QuantHub has moderate conviction in DHR. Research last updated 2026-09-23.